Intraventricular injection of antibodies to beta1-integrins generates pressure gradients in the brain favoring hydrocephalus development in rats.
In some tissues, the injection of antibodies to the beta(1)-integrins leads to a reduction in interstitial fluid pressure, indicating an active role for the extracellular matrix in tissue pressure regulation. If perturbations of the matrix occur in the periventricular area of the brain, a comparable lowering of interstitial pressures may induce transparenchymal pressure gradients favoring ventricular expansion. To examine this concept, we measured periventricular (parenchymal) and ventricular pressures with a servo-null micropipette system (2-microm tip) in adult Wistar rats before and after anti-integrin antibodies or IgG/IgM isotype controls were injected into a lateral ventricle. In a second group, the animals were kept for 2 wk after similar injections and after euthanization, the brains were removed and assessed for hydrocephalus. In experiments in which antibodies to beta(1)-integrins (n = 10) but not isotype control IgG/IgM (n = 7) were injected, we observed a decline in periventricular pressures relative to the preinjection values. Under similar circumstances, ventricular pressures were elevated (n = 10) and were significantly greater than those in the periventricular interstitium. We estimated ventricular to periventricular pressure gradients of up to 4.3 cmH(2)O. In the chronic preparations, we observed enlarged ventricles in many of the animals that received injections of anti-integrin antibodies (21 of 29 animals; 72%) but not in any animal receiving the isotype controls. We conclude that modulation/disruption of beta(1)-integrin-matrix interactions in the brain generates pressure gradients favoring ventricular expansion, suggesting a novel mechanism for hydrocephalus development.
Nagra
Gurjit
G
Brain Sciences Program and Department of Laboratory Medicine and Pathobiology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Koh
Lena
L
Aubert
Isabelle
I
Kim
Minhui
M
Johnston
Miles
M
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology*; D015170:Cerebrospinal Fluid Pressure / Q000187:drug effects / Q000502:physiology; D004195:Disease Models, Animal; D005109:Extracellular Matrix / Q000502:physiology; D006849:Hydrocephalus / Q000139:chemically induced* / Q000503:physiopathology*; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000494:pharmacology; D007075:Immunoglobulin M / Q000008:administration & dosage / Q000494:pharmacology; D007276:Injections, Intraventricular; D019012:Integrin beta1 / Q000276:immunology* / Q000502:physiology; D007427:Intracranial Pressure / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar
D000888:Antibodies, Anti-Idiotypic; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D019012:Integrin beta1